@philkeegan.bsky.social
Reposted
PURPOSE-2 results are now published. It demonstrates high level effectiveness of twice a year Lenacapavir for HIV prevention in Men and gender diverse persons.
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM
Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention
of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis
(PrEP) in cisgende...
www.nejm.org
November 28, 2024 at 12:47 PM
PURPOSE-2 results are now published. It demonstrates high level effectiveness of twice a year Lenacapavir for HIV prevention in Men and gender diverse persons.
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....
An important milestone for long acting injectables for PrEP. Now we need to address the issue of access.
www.nejm.org/doi/full/10....